by ODWAdmin | Sep 21, 2025 | Uncategorized
Proteolysis-targeting chimeras (PROTACs) have emerged as a transformative approach in drug discovery, offering event-driven protein degradation mechanisms that overcome limitations of traditional occupancy-driven inhibitors. While conventional small-molecule PROTACs...
by Jason Heaviland | Sep 19, 2025 | Uncategorized
The LNP Formulation Dilemma: How Multi-Omics Reveals Which Lipids Actually Work Your lipid nanoparticle formulation screen includes twenty candidates. Each varies in ionizable lipid structure, PEG-lipid ratio, or helper lipid composition. Standard metrics show they...
by ODWAdmin | Sep 16, 2025 | Uncategorized
One of the most challenging aspects of radioligand therapy (RLT) development is understanding why initially responsive tumors eventually develop resistance to treatment. While imaging can show when treatments stop working, it cannot reveal the underlying molecular...
by ODWAdmin | Sep 8, 2025
Combining Metabolomics, Proteomics and Transcriptomics to Reveal Key Pathways and Biomarkers Explore how reduced KRAS activity reshapes gene expression and pathway activity in HCT-116 cells. In this application note, Panome Bio combines next-generation metabolomics,...
by Jason Heaviland | Aug 22, 2025 | Uncategorized
Why Quality Systems Matter More Than You Think When you’re deeply immersed in assay development or screening potential biomarkers, regulatory compliance might understandably feel like an afterthought, given that your primary focus necessarily gravitates toward...
